Assessment of Lipophilic vs HydroPhilic Statin Therapy in Acute Myocardial Infarction: ALPS-AMI

Assessment of Lipophilic vs HydroPhilic Statin Therapy in Acute Myocardial Infarction: ALPS-AMI - Assessment of Statin Therapy in AMI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001521

Enrollment

500

Registered

2008-11-25

Start date

2008-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

Hydrophilic statin Lipophilic statin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients admitted with acute myocardial infarction (AMI), accompanied with serum low-density lipoprotein cholesterol level at 70 mg/dl or above. The diagnosis of AMI should be done following the AHA guideline, which has been documented in Circulation 2007: 116, 2634-2653.

Exclusion criteria

Exclusion criteria: 1. Advanced liver dysfunction 2. Renal failure 3. Previous history of the side effects associated with statins 4. Planned surgery for coronary artery bypass grafting 5. Known malignant disease 6. Absence of written informed consent 7. LDL cholesterol level < 70 mg/dl 8. Any other rational reason for exclusion

Design outcomes

Primary

Measure	Time frame
Death from any cause, cardiovascular death, myocardial infarction, stroke, and myocardial ischemia, which requires coronary intervention and/or coronary artery bypass grafting	—

Secondary

Measure	Time frame
Hospital admission for heart failure, and any other vascular events	—

Countries

Japan

Contacts

Public ContactResearch Center of the ALPS-AMI Study

Shinshu University School of Medicine Department of Cardiovascular Medicine

alps@shinshu-u.ac.jp0263-37-3486

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026